Careers With St. Joseph Health

Our Values are more than just words.

They form the heart and soul of St. Joseph Health and are the prime reason we attract and retain high-caliber employees who believe in the sanctity of their work in our faith-based setting.

Recent News

What does

What does "Healthy" actually mean?

| Contributor: OC Catholics Read More
Queen to receive $1.5 million for cancer care

Queen to receive $1.5 million for cancer care

| Contributor: Napa Valley Register Read More
Where tech meets health: One Year of 3D Mammography at St. Joseph Hospital

Where tech meets health: One Year of 3D Mammography at St. Joseph Hospital

| Contributor: kiem-tv Read More

Here you can find news articles and press releases from St. Joseph Health and it's locations.

About St. Joseph Health

SJH provides a full range of care facilities including 16 acute care hospitals, home health agencies, hospice care, outpatient services, skilled nursing facilities, community clinics and physician groups. All of our hospital and home health entities are accredited by the Joint Commission. In our award-winning facilities, SJH maintains a "continuum of care," matched to the diverse needs of the urban centers, smaller cities and rural communities who depend on us every day.

Giving back to the community. St. Joseph Health System Office

Lars Anker, MD

  • Neurosurgery
    (Board Certified)
100 E. Valencia Mesa Dr.
Suite 105
Fullerton, CA 92835
Accepting New Patients

Primary Office

100 E. Valencia Mesa Dr.
Suite 105
Fullerton, CA 92835
Get Directions
(714) 734-3120
(714) 446-5582
Mon - Fri: 8 a.m. - 4:30 p.m.

Secondary Office

(714) 734-3120

More Information

Medical Groups & Affiliations
  • St. Joseph Heritage Medical Group
  • St. Joseph Hospital Affiliated Physicians
  • St. Jude Affiliated Physician
  • St. Jude Heritage Medical Group
  • Meet The Doctor

    Specialties & Education

    Primary Specialties
    • Neurosurgery
    • Medical School
      University of Hamburg- Hamburg, Germany - 1994
    • Fellowship
      University of Southern California- Los Angeles, CA - 1996
    • Internship
      University of Minnesota- Minneapolis, MN - 1997
    • Residency
      University of Minnesota- Minneapolis, MN - 2001
  • Biography



    Dr. Anker is broad certified in Neurological Surgery with a focus in a variety of conditions including disorders of the nervous system, Laminectomy, Glioblastoma, and spinal disc herniation, just to name a few. He is an active member in several societies including American Association of Neurological Suregons, California Association of Neurological Surgeons, and Society of Neuro-Oncology; just to name a few.

    Dr. Anker has the best bedside manner with his patients and their families. He treats all his staff with respect and grace and is a great team leader. He is highly intelligent, driven, yet humble and easily connects with staff and patients. He is a leader that exhibits all the qualities of dignity and excellence. He frequently receives acts of appreciation from his patients, their families and his peers.

    He was the first physician to initiate a complex vaccine study at two St. Joseph Health Ministries with the St. Joseph Health System Cancer Consortium. Dr. Anker also participates in The Cancer Prevention and treatment Biospecimen Repository Protocol in 2010; Phase III Radnomized Trial of the Role of Whole Vrain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases also in 2010; Phase II double blinded placebo controlled study of Bevacizumab with or without AMG 386 in patients with recurrent Gliboblastoma or Gliosarcomma in 2013; and Phase III clinical trial evaluating DVC ax@-L, autologus dendtritic cells (DC) pulsed with tumor lysate antigen for the treatment of Glioblastoma Multiforme (GMB) in 2012.

    In 2013, he started Phase I/II Trial of Concurrent RAD001 (Everolimus) with Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma. In 2014, Dr. Ankers also Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221; Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme.